Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 4, 2019

View Archived Issues

Prion protein with gain of function found

Impaired ATM function linked to worse rheumatoid arthritis

MAC-545496, a potent inhibitor that attenuates virulence and reverses antibiotic resistance in MRSA

AXS-12 achieves primary endpoint in CONCERT phase II study in narcolepsy

Biogen reports phase II data from LILAC study of BIIB-059

Early data from first patient in phase Ib/II study of leronlimab in CCR5-poisitive mTNBC

Positive interim data reported from ongoing phase IIa combination portion of CANFOUR study

Positive topline data from part 1 of adaptive phase III RENEW study of reproxalap

Preliminary phase II results for PTG-300 in transfusion-dependent beta-thalassemia

StemoniX and Atomwise create joint venture that will initially target Rett syndrome

P. falciparum-induced malaria model created in immunocompromised juvenile mice

89Zr-DFO-MSTP-2109A shows promise as companion diagnostic in patients with mCRPC

Results form phase II study of galunisertib in MDS

Study shows how individual brain cell types contribute to AD

Vivace Therapeutics patents transcriptional coactivator YAP1/TEAD interaction inhibitors

FDA accepts IND for phase I trial of SKL-24741 for epilepsy

Sichuan Kelun-Biotech Biopharmaceutical presents ARG1-targeting PROTACs

New macrophage metalloelastase inhibitors discovered at Foresee Pharmaceuticals

Nuvation Bio discovers PARP inhibitors

Abide Therapeutics identifies new monoglyceride lipase inhibitors

Phase II trial of CNSA-001 in PKU meets primary and secondary endpoints

Xenikos initiates phase III study of T-Guard for steroid-refractory GvHD

Healthy volunteer safety data reported from phase IIb study of EB-01 in allergic contact dermatitis

Calmodulinopathy model used to study development of arrythmias

Tiziana begins phase I trial of oral foralumab in healthy volunteers